Tag: Immunotherapy
Efficacy of Durvalumab for Early-Stage TNBC Examined by Race
In Phase I/II trial of durvalumab with neoadjuvant chemo, pathological complete response rates similar for Black, non-Black patients
AUA: Immunotherapy Aids Survival in Muscle-Invasive Bladder Cancer
Patients receiving nivolumab had an approximately 30 percent lower likelihood of developing cancer recurrence versus placebo
Response to CAR-T Cell Therapy Similar for Minority Patients
Progression-free and overall survival similar for minority, nonminority patients receiving CAR-T cell therapy for non-Hodgkin lymphoma
Systemic Anticancer Treatment Not Tied to Higher COVID-19 Mortality
Receipt of immunotherapy compared with no cancer treatment in the four weeks preceding COVID-19 diagnosis associated with lower mortality
Women Face Higher Risk for Severe AEs From Cancer Therapy
Large differences in risks for severe adverse events according to sex seen for cancer patients receiving immunotherapy
Combo Immunotherapy Ups Survival in Advanced Liver Cancer
Overall survival, but not progression-free survival, improved with tremelimumab plus durvalumab versus sorafenib for unresectable HCC
Adding Immunotherapy to Chemo Ups Survival in Advanced Biliary Tract Cancer
Overall survival, progression-free survival prolonged in those receiving durvalumab versus placebo in addition to gemcitabine and cisplatin
Eltrombopag Augments Immunosuppression in Severe Aplastic Anemia
Improvement seen in the rate, rapidity, strength of hematologic response in previously untreated patients with severe aplastic anemia
High-Fiber Diet May Benefit Melanoma Patients on Immunotherapy
Higher intake of dietary fiber linked to longer progression-free survival in melanoma patients on immune checkpoint blockade
Survival Up With Tebentafusp in Metastatic Uveal Melanoma
Overall survival longer with tebentafusp for HLA*02:01-positive patients with previously untreated metastatic uveal melanoma
